Moderna shares fall 25% despite positive Phase 3 melanoma vaccine data with Merck

Moderna and Merck reported that their personalized melanoma vaccine cut recurrence or death risk by 42%, yet Moderna's stock dropped 25% on 22 October. The fall followed a leak of partial data and expectations that had run high after August's initial readout.

What happened

Moderna shares plunged 25% on 22 October after partial data from its cancer vaccine trial leaked in an unplanned way. Full results were released the same day and were positive on efficacy [1].

The Phase 3 trial tested intismeran autogene, a personalized mRNA cancer vaccine, together with Merck's Keytruda. Compared with Keytruda alone, the combination reduced the risk of melanoma recurrence or death by 42% [1][2]. The trial enrolled about 1,100 patients after surgery [2]. An Australian-led account puts the figure at 1,137 high-risk patients and describes the treatment as pairing the vaccine with pembrolizumab [3].

Six oncologists called the result a clinically meaningful advance that could become a standard of care [2]. Lead researcher Georgina Long described it as transformational [3]. The vaccine is built on encoding up to 34 tumor-specific genetic differences, and the findings are to be published in the New England Journal of Medicine [3].

The share-price reaction ran against the clinical reading. Reports attribute the drop to expectations that exceeded the results, along with concerns about the manufacturing timeline [1][2]. The vaccine is not preventative. It targets stage II-IV melanoma [3]. Regulatory approval is targeted for 2027 [2], although another account says approval could take several years [3].

How we got here

FinUties' news monitor logged 3 reports on this story from 2 outlets in recent days. It also logged 34 earlier related reports going back to 2025-11-27.

On 8 July 2026, Moderna filed a current report (Form 8-K) with the SEC [4]. The filing's contents are not described, so its link to later events is not known.

On 19 August 2026, Merck and Moderna announced positive initial Phase 3 results for the same personalized mRNA vaccine plus Keytruda in more than 1,100 higher-risk or advanced melanoma patients after surgery. The combination met its main goal of significantly extending recurrence-free survival versus Keytruda alone. It also reduced the risk of distant spread. The result built on earlier Phase 2 data [5]. At that point, U.S. approval timing was unclear, and broader oncology trials were underway [5].

That announcement fed a strong run for the stock. On 31 August 2026, CNBC's Jim Cramer reviewed August's market winners and said Moderna led them after the promising melanoma vaccine results with Merck [6]. He described the month as a comeback for S&P 500 stocks that had been pressured by bearish narratives [6].

What changed in October is the detail and the reaction. The August readout gave the headline outcome of a met main goal. The 22 October release supplied the 42% reduction in recurrence or death risk [1][2]. The partial data leak came first, and the stock then fell 25% even though full results confirmed efficacy [1]. The stock had been a leading August performer before the fall [6].

Why it matters for markets

The episode shows how a stock can fall on positive clinical news when expectations are high. If the market had priced in a stronger result, a 42% risk reduction could still read as a disappointment in share-price terms. Reports link the drop to elevated expectations and manufacturing timeline concerns [1][2].

The leak could also have contributed to volatility. Partial data reaching the market before the full release could have produced a sharp move before the complete picture was available. It is not yet known how the stock traded between the leak and the full release.

For Merck, no share-price reaction is described, so a spillover is not shown. For the wider biotech sector, no market channel is visible beyond Moderna's own move. Any read-across to other companies with personalized or mRNA-based cancer programs would be speculative.

Approval timing could matter for how the stock trades. A 2027 target for regulatory approval would put the next major milestones in the coming year [2]. A longer timeline, as another account suggests, could prolong the period in which the market weighs the data against manufacturing questions [3].

What to watch

• Publication of the full data. The New England Journal of Medicine paper could give details on the 1,137-patient trial and how the benefit held up in high-risk groups [3].
• Manufacturing timeline. Concerns about this were cited in the share-price fall [1]. Any clarification from Moderna or Merck on timing could bear on how the market treats the stock. The companies' plans are not yet known.
• Regulatory path. Approval is targeted for 2027 [2]. Whether regulators accept the data on that schedule is not yet known. Another account says approval could take several years [3].
• Further trials. Broader oncology trials of the personalized mutation-targeting approach were already underway as of August [5]. Their results could shape how the market values the platform beyond melanoma.
• Source of the leak. It is not yet known how the partial data became public, or whether any formal follow-up will occur.
• Moderna's next SEC filings. The company filed an 8-K on 8 July [4]. Further filings could clarify its commentary on the data and its plans.

Sources

1. US Top News and Analysis: Moderna shares plunge after cancer vaccine data leaks — despite positive results, 22 Oct 2026
2. US Top News and Analysis: Doctors call Moderna, Merck cancer vaccine data a major advancement — despite Wall Street reaction, 23 Oct 2026
3. Top Stories: Australia at the heart of 'transformational' cancer vaccine breakthrough, 23 Oct 2026
4. SEC EDGAR: Moderna, Inc. filed a Form 8-K, 08 Jul 2026
5. US Top News and Analysis: Personalized cancer vaccine from Moderna, Merck shows promise in first late-stage melanoma trial, 19 Aug 2026
6. US Top News and Analysis: August was the month of the comeback kids. Cramer reviews what drove the biggest winners, 31 Aug 2026

---

FinUties generates this briefing for transparency. Published after editorial review. It may summarize source data and does not provide investment recommendations. Data availability at one timestamp does not guarantee future continuity.

Provenance

• Study: event-desk-20261024-moderna-shares-fall-25-despite-positive-phase-3-melanoma-vac (a791bf7e-37ee-4ad0-9c8c-241ed6be673e)
• Author: FinUties Research
• Approved by: FinUties Research at 2026-10-24T12:48:55.078365Z
• Kind: event brief (news sources, not a FinUties dataset study)
• Cited sources: 6 from 3 outlets, all licensed for public use

• Earlier related events cited from 2026-07-08

• Manifest: /api/v1/research/studies/event-desk-20261024-moderna-shares-fall-25-despite-positive-phase-3-melanoma-vac/manifest

• Replay tolerance: append_only_sources